Skip to main content

Table 1 Characteristics of included studies

From: Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials

     EF   
Study N Centre/country Setting Levosimendan Control Levosimendan dosage Control
Landoni 2017 506 Multicenter/Italy CABG or HVR 50 (37–59) 50 (40–60) Bolus: none
Inf: 0.025 to 0.2 ug/kg/min
Duration: 48 h
Placebo
Mehta 2017 849 Multicenter/USA CABG or HVR 26 (24–32) 27 (22–31) Bolus: 0.2 ug/kg/min.
Inf: 0.1 ug/kg/min Duration: 24 h
Placebo
Cholley 2017 335 Multicenter/French CABG or HVR <40% < 40% Bolus: none
Inf: 0.1ug/kg/min Duration: 24 h
Placebo
Anastasiadis 2016 32 Single/Greece CABG or HVR 35.7 ± 4.9 37.5 ± 3.4 Bolus: none
Inf: 0.1ug/kg/min Duration: 24 h
Placebo
Baysal 2014 128 Single/Turkey HVR 35.0 (20–45) 35 (25–45) Bolus: 6ug/kg
Inf: 0.1 ug/kg/min Duration: 24 h
Standard therapy
Erb 2014 33 Single/Germany CABG or HVR 22.0 ± 4.5 22.4 ± 5.5 Bolus: none
Inf: 0.1 ug/kg/min Duration:24 h
Placebo
Levin 2012 252 Single/USA CABG < 25% < 25% Bolus:10ug/kg
Inf: 0.1 ug/kg/min Duration:24 h
Placebo
Lomivorotov 2012 60 Single/Russia CABG 28.8 ± 4.0 27.8 ± 5.4 Bolus:12ug/kg
Inf: 0.1 to 0.2 ug/kg/min Duration: 24 h
IABP
Lahtinen 2011 200 Single/Finland CABG or HVR More than 50% More than 50% Bolus: 24ug/kg
Inf: 0.2 ug/kg/min Duration: 24 h
Placebo
Tritapepe 2009 102 Single/Italy CABG 41.6 ± 10.7 44.1 ± 9.8 Bolus: 24 ug/kg
Duration: 10 min
Placebo
De Hert 2007 30 Single/Belgium CABG 24 ± 6 27 ± 3 Bolus: none
Inf: 0.1 ug/kg/min Duration: 24 h
Placebo
Tritapepe 2006 24 Single/Italy CABG 50 ± 7 52 ± 5 Bolus: 24 ug/kg
Duration: 10 min
Placebo
Al-Shawaf 2006 30 Single/Kuwait CABG 29 ± 6 31 ± 6 Bolus: 12ug/kg
Inf: 0.1 ug/kg/min Duration: 24 h
Placebo
Eriksson 2009 60 Multicenter/Finland CABG 36 ± 8 36 ± 8 Bolus: 12 ug/kg
Inf: 0.2 ug/kg/min Duration: 24 h
Placebo
Leppikangas 2011 24 Single/Finland CABG or HVR 63 ± 9 69 ± 9 Bolus: 12 ug/kg
Inf: 0.2 ug/kg/min Duration: 24 h
Placebo
Alvarez 2006 41 Single/Spain CABG or HVR 35.5 ± 4.2 33.2 ± 5.2 Bolus: 12ug/kg
Inf: 0.2 ug/kg/min Duration: 24 h
Dobutamine
Shah 2014 50 Single/India CABG 22.5 ± 4.1 22.6 ± 3.4 Bolus: none
Inf: 0.13 ug/kg/min Duration: 24 h
Placebo
  1. CABG coronary artery bypass grafting, HVR heart valve replacement, EF ejection fraction, IABP intra-aortic balloon counterpulsation, Inf infusion, USA United States of America